75 related articles for article (PubMed ID: 38484586)
1. Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions.
Thakur A; Rana M; Mishra A; Kaur C; Pan CH; Nepali K
Eur J Med Chem; 2024 Jun; 272():116472. PubMed ID: 38728867
[TBL] [Abstract][Full Text] [Related]
2. Meroterpenoids from Marine Sponge
Wang J; Yan YL; Yu XY; Pan JY; Liu XL; Hong LL; Wang B
Mar Drugs; 2024 Apr; 22(4):. PubMed ID: 38667800
[TBL] [Abstract][Full Text] [Related]
3. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
Sun Q; Zhou J; Zhang Z; Guo M; Liang J; Zhou F; Long J; Zhang W; Yin F; Cai H; Yang H; Zhang W; Gu Y; Ni L; Sai Y; Cui Y; Zhang M; Hong M; Sun J; Yang Z; Qing W; Su W; Ren Y
Cancer Biol Ther; 2014; 15(12):1635-45. PubMed ID: 25482937
[TBL] [Abstract][Full Text] [Related]
4. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.
Osude C; Lin L; Patel M; Eckburg A; Berei J; Kuckovic A; Dube N; Rastogi A; Gautam S; Smith TJ; Sreenivassappa SB; Puri N
Cells; 2022 May; 11(10):. PubMed ID: 35626731
[TBL] [Abstract][Full Text] [Related]
5. Recent development of VEGFR small molecule inhibitors as anticancer agents: A patent review (2021-2023).
Zeng J; Deng Q; Chen Z; Yan S; Dong Q; Zhang Y; Cui Y; Li L; He Y; Shi J
Bioorg Chem; 2024 May; 146():107278. PubMed ID: 38484586
[TBL] [Abstract][Full Text] [Related]
6. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).
Peng FW; Liu DK; Zhang QW; Xu YG; Shi L
Expert Opin Ther Pat; 2017 Sep; 27(9):987-1004. PubMed ID: 28621580
[TBL] [Abstract][Full Text] [Related]
7. Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy.
Liu XJ; Zhao HC; Hou SJ; Zhang HJ; Cheng L; Yuan S; Zhang LR; Song J; Zhang SY; Chen SW
Bioorg Chem; 2023 Apr; 133():106425. PubMed ID: 36801788
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Subramanian J; Morgensztern D; Govindan R
Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
[TBL] [Abstract][Full Text] [Related]
9. Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect.
Shi L; Zhou J; Wu J; Shen Y; Li X
Curr Med Chem; 2016; 23(10):1000-40. PubMed ID: 26860998
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]